Role of the Cannabinoid System in Pain Control and Therapeutic Implications for the Management of Acute and Chronic Pain Episodes
Open accessThe DOI matches its Crossref record; 179 of the 181 references it cites were found in a registry or an index, and 2 are not checked yet.
Abstract
Cannabis extracts and synthetic cannabinoids are still widely considered illegal substances. Preclinical and clinical studies have suggested that they may result useful to treat diverse diseases, including those related with acute or chronic pain. The discovery of cannabinoid receptors, their endogenous ligands, and the machinery for the synthesis, transport, and degradation of these retrograde messengers, has equipped us with neurochemical tools for novel drug design. Agonist-activated cannabinoid receptors, modulate nociceptive thresholds, inhibit release of pro-inflammatory molecules, and display synergistic effects with other systems that influence analgesia, especially the endogenous opioid system. Cannabinoid receptor agonists have shown therapeutic value against inflammatory and neuropathic pains, conditions that are often refractory to therapy. Although the psychoactive effects of these substances have limited clinical progress to study cannabinoid actions in pain mechanisms, preclinical research is progressing rapidly. For example, CB(1)mediated suppression of mast cell activation responses, CB(2)-mediated indirect stimulation of opioid receptors located in primary afferent pathways, and the discovery of inhibitors for either the transporters or the enzymes degrading endocannabinoids, are recent findings that suggest new therapeutic approaches to avoid central nervous system side effects. In this review, we will examine promising indications of cannabinoid receptor agonists to alleviate acute and chronic pain episodes. Recently, Cannabis sativa extracts, containing known doses of tetrahydrocannabinol and cannabidiol, have granted approval in Canada for the relief of neuropathic pain in multiple sclerosis. Further double-blind placebo-controlled clinical trials are needed to evaluate the potential therapeutic effectiveness of various cannabinoid agonists-based medications for controlling different types of pain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The capsaicin receptor: a heat-activated ion channel in the pain pathway
Caterina, M. J., Schumacher, M. A., Tominaga, M., Rosen, T. A., Levine, J. D., & Julius, D. (1997) · Nature · doi:10.1038/39807 · Cited by 9,107
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633 · cited 1×
“The first endocannabinoid isolated (from porcine brain) and structurally characterised was arachidonylethanolamide (AEA), commonly designated anandamide [30].”
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092 · cited 2×
“Two have been cloned, type 1 (CB1) and type 2 (CB2) cannabinoid receptors [100, 108], while the other two, WIN and abnormal-cannabidiol (abn-CBD) receptors (the latter also known as anandamide receptor), have been characterised pharmacologically [8, 31, 51, 71, 107].”
Structure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011 · cited 2×
“Two have been cloned, type 1 (CB1) and type 2 (CB2) cannabinoid receptors [100, 108], while the other two, WIN and abnormal-cannabidiol (abn-CBD) receptors (the latter also known as anandamide receptor), have been characterised pharmacologically [8, 31, 51, 71, 107].”
Ledent, C., Valverde, O., Cossu, G., Petitet, F., Aubert, J.-F., Beslot, F., Böhme, G. A., Imperato, A., Pedrazzini, T., Roques, B. P., et al. (1999) · Science · doi:10.1126/science.283.5400.401 · Cited by 3,614 · cited 2×
“A number of synthetic cannabinoid receptor agonists and antagonists have been formulated and genetically modified mice have been produced [13, 27, 86].”
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913
Determination and characterization of a cannabinoid receptor in rat brain
Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S., & Howlett, A. C. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09876-1 · Cited by 2,443 · cited 1×
“In the late 1980s, Howlett and colleagues [29] identified and characterised a receptor in rat brain that met criteria for a high-affinity, stereoselective, pharmacologically distinct cannabinoid receptor, by means of radiolabelled agonist ligand binding and functional assays for G-protein coupled…”
Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish
Gaoni, Y., & Mechoulam, R. (1964) · Journal of the American Chemical Society · doi:10.1021/ja01062a046 · Cited by 2,393 · cited 1×
“In 1964, Mechoulam and colleagues [42] found that delta-9-tetrahydrocannabinol (THC) was the major psychoactive ingredient of cannabis.”
Herkenham, M., Lynn, A., Johnson, M., Melvin, L., de Costa, B., & Rice, K. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-02-00563.1991 · Cited by 2,159 · cited 1×
“Their distribution has been mapped by autoradiographic studies, immunohistochemical techniques, in situ histochemistry, and electrophysiological studies [53, 78, 140].”
Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses
Wilson, R. I., & Nicoll, R. A. (2001) · Nature · doi:10.1038/35069076 · Cited by 1,607 · cited 1×
“However, if the CB1 receptor agonist remains present, the depolarisation phenomenon is blocked by occlusion [115, 175] and inhibitory inputs are transient.”
Formation and inactivation of endogenous cannabinoid anandamide in central neurons
Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J.-C., & Piomelli, D. (1994) · Nature · doi:10.1038/372686a0 · Cited by 1,587 · cited 3×
“It is synthesised by cleavage of an inositol-1,2-diacylglycerol, which is catalysed by phospholipase C [16, 32].”
Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system
Tsou, K., Brown, S., Sañudo-Peña, M. C., Mackie, K., & Walker, J. M. (1998) · Neuroscience · doi:10.1016/s0306-4522(97)00436-3 · Cited by 1,586
Role of Endogenous Cannabinoids in Synaptic Signaling
FREUND, T. F., KATONA, I., & PIOMELLI, D. (2003) · Physiological Reviews · doi:10.1152/physrev.00004.2003 · Cited by 1,574
A second endogenous cannabinoid that modulates long-term potentiation
Stella, N., Schweitzer, P., & Piomelli, D. (1997) · Nature · doi:10.1038/42015 · Cited by 1,496 · cited 1×
“The endogenous cannabinoid 2-AG is produced by neurons and other nervous cells in a stimulus-dependent manner, binds to cannabinoid receptors and undergoes rapid biological inactivation through transport into cells and catalytic hydrolysis [103, 151].”
Anthony, J. C., Warner, L. A., & Kessler, R. C. (1994) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.2.3.244 · Cited by 1,341
Cravatt, B. F., Demarest, K., Patricelli, M. P., Bracey, M. H., Giang, D. K., Martin, B. R., & Lichtman, A. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161191698 · Cited by 1,310 · cited 2×
“A number of synthetic cannabinoid receptor agonists and antagonists have been formulated and genetically modified mice have been produced [13, 27, 86].”
Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice
Zimmer, A., Zimmer, A. M., Hohmann, A. G., Herkenham, M., & Bonner, T. I. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5780 · Cited by 1,064 · cited 1×
“In these mice, lacking functional CB1 receptors, certain cannabinoid receptor agonists have antinociceptive effects in the hot-plate or formalin tests [179].”
Huang, S. M., Bisogno, T., Trevisani, M., Al-Hayani, A., De Petrocellis, L., Fezza, F., Tognetto, M., Petros, T. J., Krey, J. F., Chu, C. J., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122196999 · Cited by 964 · cited 2×
“NADA was identified in rat and bovine brain [65], activates CB1 (and VR1 receptors) and elicits cannabimimetic effects, including analgesia, following systemic administration.”
Functional characteristics of the midbrain periaqueductal gray.
Behbehani, M. M. (1995) · Progress in Neurobiology · doi:10.1016/0301-0082(95)00009-k · Cited by 879 · cited 2×
“These receptors are distributed similarly in areas of the central nervous system that participate in antinociception, such as the PAG or substantia gelatinosa [5, 80, 87, 97, 116, 176].”
Kreitzer, A. C., & Regehr, W. G. (2001) · Neuron · doi:10.1016/s0896-6273(01)00246-x · Cited by 875 · cited 4×
“CB 1 receptor antagonists block DSI and DSE.”
InfluentialOhno-Shosaku, T., Maejima, T., & Kano, M. (2001) · Neuron · doi:10.1016/s0896-6273(01)00247-1 · Cited by 845 · cited 1×
“However, if the CB1 receptor agonist remains present, the depolarisation phenomenon is blocked by occlusion [115, 175] and inhibitory inputs are transient.”
2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB 1 receptor
Hanuš, L., Abu-Lafi, S., Fride, E., Breuer, A., Vogel, Z., Shalev, D. E., Kustanovich, I., & Mechoulam, R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.061029898 · Cited by 762 · cited 1×
“Noladin ether, or 2-arachidonylglyceryl-ether, has been isolated from porcine brain and is an endocannabinoid that binds to CB1 cannabinoid receptor to signal food consumption and weight control [52].”
Cannabinoid receptors and pain
Pertwee, R. G. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00031-9 · Cited by 741
Iversen, L. (2003) · Brain · doi:10.1093/brain/awg143 · Cited by 732 · cited 1×
“Cannabinoid receptor agonists effects in the central nervous system (CNS) include disruption of psychomotor behaviour, short-term memory impairment, intoxication, stimulation of appetite, antiemetic effects, and antinociceptive actions [68].”
Clinical Uses of α2-Adrenergic Agonists
Kamibayashi, T., Maze, M., Weiskopf, R. B., Weiskopf, R. B., & Todd, M. M. (2000) · Anesthesiology · doi:10.1097/00000542-200011000-00030 · Cited by 714
Alpha‐2 and imidazoline receptor agonistsTheir pharmacology and therapeutic role
Khan, Z. P., Ferguson, C. N., & Jones, R. M. (1999) · Anaesthesia · doi:10.1046/j.1365-2044.1999.00659.x · Cited by 686
Modulation of transmitter release via presynaptic cannabinoid receptors
Schlicker, E., & Kathmann, M. (2001) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01805-8 · Cited by 671 · cited 1×
“2) [79] [141].”
Katona, I., Rancz, E. A., Acsády, L., Ledent, C., Mackie, K., Hájos, N., & Freund, T. F. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-23-09506.2001 · Cited by 668 · cited 1×
“Their distribution has been mapped by autoradiographic studies, immunohistochemical techniques, in situ histochemistry, and electrophysiological studies [53, 78, 140].”
Porter, A. C., Sauer, J.-M., Knierman, M. D., Becker, G. W., Berna, M. J., Bao, J., Nomikos, G. G., Carter, P., Bymaster, F. P., Leese, A. B., et al. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.3.1020 · Cited by 615 · cited 3×
“Other endogenous ligands for cannabinoid receptors are 2-arachidonoylglycerol (2-AG), noladin ether, virodhamine, and N-arachidonoyldopamine (NADA) [103] [121] [168]; although anandamide is the endocannabinoid most extensively studied.”
InfluentialCannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review
Tramèr, M. R., Carroll, D., Campbell, F. A., Reynolds, D. J. M., Moore, R. A., & McQuay, H. J. (2001) · BMJ · doi:10.1136/bmj.323.7303.16 · Cited by 610 · cited 2×
“Cardiovascular effects are generally moderate and well tolerated: hypotension can appear in comparison with placebo [158, 165], but no more than with codeine.”
Shen, M., Piser, T. M., Seybold, V. S., & Thayer, S. A. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-14-04322.1996 · Cited by 604 · cited 1×
“However, even though cannabinoid receptor-mediated inhibition of glutamatergic transmission occurs in some brain regions including PAG neurons [162], it has not been detected in the medullary dorsal horn [143, 154, 162].”
Járai, Z., Wagner, J. A., Varga, K., Lake, K. D., Compton, D. R., Martin, B. R., Zimmer, A. M., Bonner, T. I., Buckley, N. E., Mezey, E., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.24.14136 · Cited by 599 · cited 1×
“Two have been cloned, type 1 (CB1) and type 2 (CB2) cannabinoid receptors [100, 108], while the other two, WIN and abnormal-cannabidiol (abn-CBD) receptors (the latter also known as anandamide receptor), have been characterised pharmacologically [8, 31, 51, 71, 107].”
Wade, D. T., Makela, P., Robson, P., House, H., & Bateman, C. (2004) · Multiple Sclerosis Journal · doi:10.1191/1352458504ms1082oa · Cited by 589 · cited 3×
“Cannabidiol (CBD) is another major constituent of the Cannabis sativa plant, having the same therapeutic effects than THC (analgesic, anti-inflammatory, and others), but with a different pharmacologic profile.”
Pharmacology of spinal adrenergic systems which modulate spinal nociceptive processing
Yaksh, T. L. (1985) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(85)90537-4 · Cited by 586 · cited 2×
“These receptors are distributed similarly in areas of the central nervous system that participate in antinociception, such as the PAG or substantia gelatinosa [5, 80, 87, 97, 116, 176].”
Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor
Buckley, N. E., McCoy, K. L., Mezey, É., Bonner, T., Zimmer, A., Felder, C. C., Glass, M., & Zimmer, A. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00211-9 · Cited by 544 · cited 1×
“A number of synthetic cannabinoid receptor agonists and antagonists have been formulated and genetically modified mice have been produced [13, 27, 86].”
Evidence for a New G Protein-Coupled Cannabinoid Receptor in Mouse Brain
Breivogel, C. S., Griffin, G., Di Marzo, V., & Martin, B. R. (2001) · Molecular Pharmacology · doi:10.1124/mol.60.1.155 · Cited by 541 · cited 3×
“Two have been cloned, type 1 (CB1) and type 2 (CB2) cannabinoid receptors [100, 108], while the other two, WIN and abnormal-cannabidiol (abn-CBD) receptors (the latter also known as anandamide receptor), have been characterised pharmacologically [8, 31, 51, 71, 107].”
Howlett, A. C. (2002) · Prostaglandins & Other Lipid Mediators · doi:10.1016/s0090-6980(02)00060-6 · Cited by 535
Ibrahim, M. M., Porreca, F., Lai, J., Albrecht, P. J., Rice, F. L., Khodorova, A., Davar, G., Makriyannis, A., Vanderah, T. W., Mata, H. P., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409888102 · Cited by 521 · cited 4×
“On the other hand, as mentioned earlier, new CB2 receptor properties are being discovered, as it has been confirmed that they indirectly stimulate opioid receptors located in primary afferent pathways [67].”
InfluentialCannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors
Richardson, J. D., Kilo, S., & Hargreaves, K. M. (1998) · Pain · doi:10.1016/s0304-3959(97)00213-3 · Cited by 500 · cited 1×
“In opposition, other authors suggest that there is baseline endogenous cannabinoid activity at the spinal level, as intrathecal administration of the CB1 receptor antagonist SR141716A induces hyperalgesic effects [132, 134].”
Ibrahim, M. M., Deng, H., Zvonok, A., Cockayne, D. A., Kwan, J., Mata, H. P., Vanderah, T. W., Lai, J., Porreca, F., Makriyannis, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1834309100 · Cited by 491 · cited 2×
“Peripheral cannabinoid receptors are less abundant than in central nervous system areas and non-neuronal cells located near nociceptive neuronal nerve endings are involved in the modulation of pro-inflammatory factors released [66, 146, 160].”
Pain modulation by release of the endogenous cannabinoid anandamide
Walker, J. M., Huang, S. M., Strangman, N. M., Tsou, K., & Sañudo-Peña, M. C. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.21.12198 · Cited by 485
Wade, D. T., Robson, P., House, H., Makela, P., & Aram, J. (2003) · Clinical Rehabilitation · doi:10.1191/0269215503cr581oa · Cited by 441 · cited 1×
“Cardiovascular effects are generally moderate and well tolerated: hypotension can appear in comparison with placebo [158, 165], but no more than with codeine.”
Molecular characterization of human and mouse fatty acid amide hydrolases
Giang, D. K., & Cravatt, B. F. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2238 · Cited by 429 · cited 1×
“Another promising target for therapeutic intervention is the fatty acid amide hydrolase (FAAH) enzyme, which is responsible for intracellular anandamide degradation [43].”
Hájos, N., Ledent, C., & Freund, T. F. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00287-1 · Cited by 419 · cited 3×
“Two have been cloned, type 1 (CB1) and type 2 (CB2) cannabinoid receptors [100, 108], while the other two, WIN and abnormal-cannabidiol (abn-CBD) receptors (the latter also known as anandamide receptor), have been characterised pharmacologically [8, 31, 51, 71, 107].”
Zhang, J., Hoffert, C., Vu, H. K., Groblewski, T., Ahmad, S., & O'Donnell, D. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02704.x · Cited by 419 · cited 1×
“Moreover, the appearance of CB2 expression coincides with the appearance of activated microglia [178].”
The neurobiology and evolution of cannabinoid signalling
Elphick, M. R., & Egertova, M. (2001) · Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences · doi:10.1098/rstb.2000.0787 · Cited by 417 · cited 1×
“Thus CB1 receptors and FAAH have a close and complementary anatomical distribution [34].”
An analgesia circuit activated by cannabinoids
Meng, I. D., Manning, B. H., Martin, W. J., & Fields, H. L. (1998) · Nature · doi:10.1038/26481 · Cited by 411 · cited 3×
“Temporary inactivation of neural activity in the RVM in rat brainstem circumvents the analgesic effects of systemically administered cannabinoids, while leaving motor activity effects untouched [104].”
Cadas, H., di Tomaso, E., & Piomelli, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-04-01226.1997 · Cited by 396 · cited 2×
“It is synthesised by cleavage of an inositol-1,2-diacylglycerol, which is catalysed by phospholipase C [16, 32].”
Di Marzo, V., Breivogel, C. S., Tao, Q., Bridgen, D. T., Razdan, R. K., Zimmer, A. M., Zimmer, A., & Martin, B. R. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0752434.x · Cited by 393
Pharmacological and biochemical interactions between opioids and cannabinoids
Manzanares, J., Corchero, J., Romero, J., Fernández-Ruiz, J. J., Ramos, J. A., & Fuentes, J. A. (1999) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(99)01339-5 · Cited by 392 · cited 2×
“CB1, 2-adrenergic, and -opioid receptors are all Gprotein coupled receptors sharing signal transduction pathways, such as those inhibiting adenylate cyclase and modulating K + and Ca 2+ channels activity [24, 62, 80, 94, 124].”
Self-citationKozak, K. R., Rowlinson, S. W., & Marnett, L. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m007088200 · Cited by 390 · cited 1×
“COX-2 exerts a negative influence on endocannabinoids because it catabolises them (as anandamide and 2-AG, that have shown neuroprotective properties in the injured brain) [83].”
Fox, A., Kesingland, A., Gentry, C., McNair, K., Patel, S., Urban, L., & James, I. (2001) · Pain · doi:10.1016/s0304-3959(00)00474-7 · Cited by 379
The analgesic properties of delta‐9‐tetrahydrocannabinol and codeine
Noyes, R., Brunk, S. F., Avery, D. H., & Canter, A. (1975) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt197518184 · Cited by 378
Przewłocki, R., & Przewłocka, B. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)01308-5 · Cited by 367 · cited 1×
“CB1, 2-adrenergic, and -opioid receptors are all Gprotein coupled receptors sharing signal transduction pathways, such as those inhibiting adenylate cyclase and modulating K + and Ca 2+ channels activity [24, 62, 80, 94, 124].”
Berman, J. S., Symonds, C., & Birch, R. (2004) · Pain · doi:10.1016/j.pain.2004.09.013 · Cited by 362
Cerebellar Depolarization-Induced Suppression of Inhibition Is Mediated by Endogenous Cannabinoids
Kreitzer, A. C., & Regehr, W. G. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-20-j0005.2001 · Cited by 358 · cited 4×
“CB 1 receptor antagonists block DSI and DSE.”
InfluentialCompton, D. R., Aceto, M. D., Lowe, J., & Martin, B. R. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12911-x · Cited by 357 · cited 2×
“It has been suggested that although CB1 receptor antagonists block the antinociceptive effects of cannabinoid receptor agonists, the antagonists by themselves do not alter baseline pain thresholds [22].”
Cannabinoids inhibit neurodegeneration in models of multiple sclerosis
Pryce, G., Ahmed, Z., Hankey, D. J. R., Jackson, S. J., Croxford, J. L., Pocock, J. M., Ledent, C., Petzold, A., Thompson, A. J., Giovannoni, G., et al. (2003) · Brain · doi:10.1093/brain/awg224 · Cited by 342
Karst, M., Salim, K., Burstein, S., Conrad, I., Hoy, L., & Schneider, U. (2003) · JAMA · doi:10.1001/jama.290.13.1757 · Cited by 340
Cannabinoids and neuroinflammation
Walter, L., & Stella, N. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705667 · Cited by 336
Todd, A. J., & Spike, R. C. (1993) · Progress in Neurobiology · doi:10.1016/0301-0082(93)90045-t · Cited by 330 · cited 1×
“Superficial dorsal horn CB1 receptors are mainly present in GABAergic neurons [157].”
An Amino-terminal Variant of the Central Cannabinoid Receptor Resulting from Alternative Splicing
Shire, D., Carillon, C., Kaghad, M., Calandra, B., Rinaldi-Carmona, M., Fur, G. L., Caput, D., & Ferrara, P. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.8.3726 · Cited by 330 · cited 1×
“In addition, some truncated forms of the CB1 receptor, like the CB1A, have been found, resulting from alternative splicing [144]; and there may be more subtypes of cannabinoid receptors yet undiscovered [8, 51].”
The Perceived Effects of Smoked Cannabis on Patients with Multiple Sclerosis
Consroe, P., Musty, R., Rein, J., Tillery, W., & Pertwee, R. (1997) · European Neurology · doi:10.1159/000112901 · Cited by 323
Herzberg, U., Eliav, E., Bennett, G. J., & Kopin, I. J. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(96)13308-5 · Cited by 307
Notcutt, W., Price, M., Miller, R., Newport, S., Phillips, C., Simmons, S., & Sansom, C. (2004) · Anaesthesia · doi:10.1111/j.1365-2044.2004.03674.x · Cited by 305 · cited 3×
“Cannabidiol (CBD) is another major constituent of the Cannabis sativa plant, having the same therapeutic effects than THC (analgesic, anti-inflammatory, and others), but with a different pharmacologic profile.”
Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons
Ahluwalia, J., Urban, L., Capogna, M., Bevan, S., & Nagy, I. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00389-4 · Cited by 302 · cited 1×
“high degree, giving further support to a complementary role for these receptors [1].”
Hohmann, A. G., & Herkenham, M. (1999) · Neuroscience · doi:10.1016/s0306-4522(98)00524-7 · Cited by 301
Valenzano, K. J., Tafesse, L., Lee, G., Harrison, J. E., Boulet, J. M., Gottshall, S. L., Mark, L., Pearson, M. S., Miller, W., Shan, S., et al. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.12.008 · Cited by 288
Antihyperalgesic effects of spinal cannabinoids
Richardson, J. D., Aanonsen, L., & Hargreaves, K. M. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01621-x · Cited by 275 · cited 1×
“Thus, cannabinoid compounds can modulate hyperalgesia of various origins and they are effective even in inflammatory and neuropathic pain [10, 133], which are conditions often refractory to treatment.”
Analgesic Effect of Delta‐9‐Tetrahydrocannabinol
NOYES, R., BRUNK, S. F., BARAM, D. A., & CANTER, A. (1975) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1975.tb02348.x · Cited by 273
Structural determinants for recognition and translocation by the anandamide transporter
Piomelli, D., Beltramo, M., Glasnapp, S., Lin, S. Y., Goutopoulos, A., Xie, X.-Q., & Makriyannis, A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5802 · Cited by 268 · cited 1×
“Some interesting products are the anandamide reuptake inhibitors which inhibit its transport and potentiate its analgesic effects; as N-(4-hydroxyphenyl)-arachidonamide (AM 404), an anandamide analogue [119], and N-(3-furylmethyl) eicosa-5,8,11,14-tetraenamide (UCM707) (Fig.”
Cannabinoid CB1 Receptor Expression in Rat Spinal Cord
Farquhar-Smith, W. P., Egertová, M., Bradbury, E. J., McMahon, S. B., Rice, A. S. C., & Elphick, M. R. (2000) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2000.0844 · Cited by 268 · cited 3×
“CB1 receptors of the spinal cord dorsal horn are predominantly found in interneurons, particularly in a double band of CB1 immunoreactivity in laminae I, II, and inner/III transition, and in lamina X [35].”
Therapeutic aspects of cannabis and cannabinoids
Robson, P. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.178.2.107 · Cited by 265 · cited 1×
“es “panacea”, or “cure-all”, and were sold as a legal medicine, mainly for pain [12, 135].”
Vaney, C., Heinzel-Gutenbrunner, M., Jobin, P., Tschopp, F., Gattlen, B., Hagen, U., Schnelle, M., & Reif, M. (2004) · Multiple Sclerosis Journal · doi:10.1191/1352458504ms1048oa · Cited by 262
Lichtman, A. H., Cook, S. A., & Martin, B. R. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12310-0 · Cited by 260 · cited 4×
“CB1 receptors are also expressed in cells of the midbrain periaqueductal grey matter (PAG), and in the substantia gelatinosa of the spinal cord (receiving nociceptive input from primary afferent neurons), which are key sites for modulating nociceptive information [87, 92, 106].”
InfluentialHowlett, A. C., Johnson, M. R., Melvin, L. S., & Milne, G. M. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13196-9 · Cited by 253 · cited 1×
“Moreover, they found a correlation between the potency of cannabinoid compounds in producing analgesia in vivo and the inhibition of adenylcyclase in vitro, indicating the presence of a G-proteincoupled “cannabinoid analgesic receptor” in brain [64].”
GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus
Katona, I., Sperlágh, B., Maglóczky, Z., Sántha, E., Köfalvi, A., Czirják, S., Mackie, K., Vizi, E. S., & Freund, T. F. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00286-4 · Cited by 244 · cited 1×
“2) [79] [141].”
Vaughan, C. W., Connor, M., Bagley, E. E., & Christie, M. J. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)23200-4 · Cited by 241 · cited 8×
“The cellular actions of cannabinoids on supraspinal and spinal descending antinociception pathways have also been studied [56, 162, 163].”
InfluentialThe endocannabinoid nervous system
Porter, A. C., & Felder, C. C. (2001) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(01)00130-9 · Cited by 227 · cited 2×
“Clinical trials have shown that nonselective cannabinoid receptor agonists are relatively safe and therapeutically efficacious, but they also induce psychotropic side effects [120].”
Mechanisms of Endocannabinoid Inactivation: Biochemistry and Pharmacology
Giuffrida, A., Beltramo, M., & Piomelli, D. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29345-9 · Cited by 226 · cited 1×
“Thereafter, they are rapidly inactivated by a combination of a transporter mechanism and further enzyme degradation [32, 44, 118].”
Watson, S. J. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.6.547 · Cited by 226 · cited 1×
“As for clinical applications, one of the best documented therapeutic uses of cannabinoid derivatives, and the one most widely approved today, is as an antiemetic drug [12, 158, 172].”
Bridges, D., Ahmad, K., & Rice, A. S. C. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704110 · Cited by 221
Spinal and supraspinal components of cannabinoid-induced antinociception.
Lichtman, A. H., & Martin, B. R. (1991) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20242-7 · Cited by 217 · cited 4×
“For this reason, it has been suggested that cannabinoids are paradoxically hyperalgesic at the level of the medullary dorsal horn because of their selective inhibition of GABAergic and glycinergic transmission [56, 89], an effect that appears to be mediated by CB1 receptors located presynaptically in interneurons.”
InfluentialBoger, D. L., Miyauchi, H., Du, W., Hardouin, C., Fecik, R. A., Cheng, H., Hwang, I., Hedrick, M. P., Leung, D., Acevedo, O., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049614v · Cited by 214 · cited 1×
“Indeed, reversible FAAH inhibitors produce analgesia in animal models [7].”
Activational role of cannabinoids on movement
Sañudo-Peña, M. C., Romero, J., Seale, G. E., Fernandez-Ruiz, J. J., & Walker, J. M. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00044-3 · Cited by 210 · cited 1×
“…since most responses are quantified by behavioural tests, it is important to remember that cannabinoids may inhibit or enhance motor activity [139], depending on the dose and structure of the compound administered, which may influence behavioural reactions and mask the results of analgesic…”
Grinspoon, L. (1969) · Scientific American · doi:10.1038/scientificamerican1269-17 · Cited by 209
Naef, M., Curatolo, M., Petersen-Felix, S., Arendt-Nielsen, L., Zbinden, A., & Brenneisen, R. (2003) · Pain · doi:10.1016/s0304-3959(03)00163-5 · Cited by 209
Welch, S. P., & Stevens, D. L. (1992) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10720-9 · Cited by 206 · cited 2×
“Interestingly, this action is inhibited by either cannabinoid or opioid receptors antagonists separately, as demonstrated in acute [41] and chronic pain models [147, 174].”
Kohno, T., Kumamoto, E., Higashi, H., Shimoji, K., & Yoshimura, M. (1999) · The Journal of Physiology · doi:10.1111/j.1469-7793.1999.0803p.x · Cited by 196 · cited 2×
“For instance, -opioid receptor agonists inhibit release of glutamate from primary afferent terminals at the level of the spinal and medullary dorsal horn, while CB1 receptors do not have any inhibitory effect on those excitatory neurons [49, 81].”
Lim, G., Sung, B., Ji, R.-R., & Mao, J. (2003) · Pain · doi:10.1016/s0304-3959(03)00242-2 · Cited by 195 · cited 1×
“For example, animal models of neuropathic pain stimulate upregulation of CB1 receptors expression in nervous structures involved in the processing of pain, like the ipsilateral superficial spinal cord dorsal horn [90] or contralateral thalamus [145], enhancing the analgesic effects of cannabinoid receptor agonists.”
Cannabinoid receptors undergo axonal flow in sensory nerves
Hohmann, A. G., & Herkenham, M. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00220-1 · Cited by 194 · cited 1×
“…in neurons of the rat dorsal root ganglia (that express neuropeptide markers found in nociceptive primary afferents) [59], and these receptors are transported both centrally, reaching superficial dorsal horn terminals [59] and peripherally towards peripheral nerve terminals of sensory nerves [58].”
Cannabis use for chronic non-cancer pain: results of a prospective survey
Ware, M. A., Doyle, C. R., Woods, R., Lynch, M. E., & Clark, A. J. (2003) · Pain · doi:10.1016/s0304-3959(02)00400-1 · Cited by 185
Lack of analgesic efficacy of oral δ-9-tetrahydrocannabinol in postoperative pain
Buggy, D. J., Toogood, L., Maric, S., Sharpe, P., Lambert, D. G., & Rowbotham, D. J. (2003) · Pain · doi:10.1016/s0304-3959(03)00331-2 · Cited by 184
Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy
Rice, A. S. C., Farquhar-Smith, W. P., & Nagy, I. (2002) · Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA) · doi:10.1054/plef.2001.0362 · Cited by 183 · cited 1×
“Possible mechanisms of this CB2-mediated effect include the attenuation of NGF-induced mast cell degranulation and of neutrophil accumulation, both of which are processes known to contribute to the generation of inflammatory hyperalgesia [131].”
Cannabinoids and multiple sclerosis
Pertwee, R. G. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00255-3 · Cited by 181
Martin, W. J., Hohmann, A. G., & Walker, J. M. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-20-06601.1996 · Cited by 172 · cited 1×
“1B) [93] [99].”
Bridges, D., Rice, A. S. C., Egertová, M., Elphick, M. R., Winter, J., & Michael, G. J. (2003) · Neuroscience · doi:10.1016/s0306-4522(03)00200-8 · Cited by 172 · cited 2×
“Finally, CB 1 receptors are found on only a small percentage of C-fibres, while the majority are on axons of larger diameter neurons with myelinated Afibres [11].”
Tjølsen, A., & Hole, K. (1997) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-60777-6_1 · Cited by 167 · cited 1×
“Pain perception of a hot-plate is thought to be mediated by a central mechanism (eliciting supraspinally controlled behavioural responses to the noxious heat stimulus), whereas the second late phase of response to an intraplantar injection of formalin reflects peripheral inflammatory pain mechanisms [156].”
Martin, W. J., Coffin, P. O., Attias, E., Balinsky, M., Tsou, K., & Walker, J. M. (1999) · Brain Research · doi:10.1016/s0006-8993(98)01368-7 · Cited by 164
Cannabinoids: a real prospect for pain relief
Iversen, L. (2002) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(01)00120-5 · Cited by 162 · cited 2×
“In this context, cannabinoids block spinal c-fos expression in response to noxious stimulation and suppress the electrophysiologic responses of spinal cord neurons [69] [116] [166].”
Endogenous Cannabinoid Signaling
Piomelli, D., Beltramo, M., Giuffrida, A., & Stella, N. (1998) · Neurobiology of Disease · doi:10.1006/nbdi.1998.0221 · Cited by 159 · cited 2×
“In addition, other compounds like the N-acylethanolamines block anandamide degradation [118].”
Takano, Y., & Yaksh, T. L. (1992) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)11102-6 · Cited by 156 · cited 1×
“However, some studies suggest that the antinociceptive actions of 2-adrenergic receptors are mediated purely at the spinal level, mainly via A-subtype 2adrenergic receptors present in the substantia gelatinosa [76, 155].”
Smith, F. L., Fujimori, K., Lowe, J., & Welch, S. P. (1998) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(97)00583-2 · Cited by 154 · cited 1×
“Interestingly, this action is inhibited by either cannabinoid or opioid receptors antagonists separately, as demonstrated in acute [41] and chronic pain models [147, 174].”
Patterns of cannabis use among patients with multiple sclerosis
Clark, A. J., Ware, M. A., Yazer, E., Murray, T. J., & Lynch, M. E. (2004) · Neurology · doi:10.1212/01.wnl.0000127707.07621.72 · Cited by 153
Evaluation of Intramuscular Levonantradol and Placebo in Acute Postoperative Pain
JAIN, A. K., RYAN, J. R., McMAHON, F. G., & SMITH, G. (1981) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1981.tb02610.x · Cited by 150 · cited 1×
“It has been used in clinical trials to palliate postoperative pain or pain due to trauma and has shown more analgesic efficacy than placebo [70].”
Morisset, V., & Urban, L. (2001) · Journal of Neurophysiology · doi:10.1152/jn.2001.86.1.40 · Cited by 150 · cited 2×
“CB1 receptors are also expressed in cells of the midbrain periaqueductal grey matter (PAG), and in the substantia gelatinosa of the spinal cord (receiving nociceptive input from primary afferent neurons), which are key sites for modulating nociceptive information [87, 92, 106].”
SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice
Richardson, J. D., Aanonsen, L., & Hargreaves, K. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(96)00952-1 · Cited by 149 · cited 1×
“In opposition, other authors suggest that there is baseline endogenous cannabinoid activity at the spinal level, as intrathecal administration of the CB1 receptor antagonist SR141716A induces hyperalgesic effects [132, 134].”
Fatty Acid Sulfonyl Fluorides Inhibit Anandamide Metabolism and Bind to the Cannabinoid Receptor
Deutsch, D. G., Lin, S., Hill, W. A. G., Morse, K. L., Salehani, D., Arreaza, G., Omeir, R. L., & Makriyannis, A. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6072 · Cited by 146 · cited 1×
“AM374 (palmitylsulfonyl fluoride) is a potent FAAH inhibitor [28], preventing the hydrolysis of endocannabinoids and, therefore, increasing their synaptic levels and elevating cannabinoid receptors activity (Fig.”
Cannabinoids and Multiple Sclerosis
Pertwee, R. G. (2007) · Molecular Neurobiology · doi:10.1007/s12035-007-0005-2 · Cited by 145 · cited 2×
“The THC analogues most often used for preclinical or therapeutic purposes in humans are dronabinol, nabilone, levonantradol , CT-3 (or ajulemic acid), and HU211 [15, 117].”
The neuronal distribution of cannabinoid receptor type 1 in the trigeminal ganglion of the rat
Price, T. J., Helesic, G., Parghi, D., Hargreaves, K., & Flores, C. M. (2003) · Neuroscience · doi:10.1016/s0306-4522(03)00333-6 · Cited by 144 · cited 1×
“On the other hand, although CB1 receptor mRNA expression has been described in the trigeminal ganglia in medium and large diameter neurons, the majority of these CB1-expressing neurons do not seem to be involved in nociceptive neurotransmission in the noninjured animal [122].”
Cannabinoids inhibit excitatory neurotransmission in the substantia nigra pars reticulata
Szabó, B., Wallmichrath, I., Mathonia, P., & Pfreundtner, C. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00036-1 · Cited by 140
Vaughan, C. W., McGregor, I. S., & Christie, M. J. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702636 · Cited by 137 · cited 10×
“Two have been cloned, type 1 (CB 1 ) and type 2 (CB 2 ) cannabinoid receptors [100] [108], while the other two, WIN and abnormal-cannabidiol (abn-CBD) receptors (the latter also known as anandamide receptor), have been characterised pharmacologically [8] [31] [51] [71] [107].”
InfluentialThe neurobiology of cannabinoid analgesia
Walker, J. M., Hohmann, A. G., Martin, W. J., Strangman, N. M., Huang, S. M., & Tsou, K. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00289-1 · Cited by 134 · cited 2×
“In the CNS, although CB2 receptor mRNA has not been detected in the neuronal tissue of human or rat brain, a role in antinociception in inflammatory processes of the nervous system cannot be excluded due to its presence in activated microglia [166].”
Brenneisen, R., Egli, A., ElSohly, M. A., Henn, V. S., & Spiess, Y. (1996) · PubMed · Cited by 134
Endocannabinoids and related fatty acid derivatives in pain modulation
Walker, J. M., Krey, J. F., Chu, C. J., & Huang, S. M. (2002) · Chemistry and Physics of Lipids · doi:10.1016/s0009-3084(02)00152-4 · Cited by 131
Antinociceptive, subjective and behavioral effects of smoked marijuana in humans
Greenwald, M. K., & Stitzer, M. L. (2000) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(99)00128-3 · Cited by 131 · cited 2×
“2000 [46] Healthy volunteers being regular”
A role for endocannabinoids in indomethacin-induced spinal antinociception
Gühring, H., Hamza, M., Sergejeva, M., Ateş, M., Kotalla, C., Ledent, C. A., & Brune, K. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)02485-8 · Cited by 129 · cited 1×
“In the same way, indomethacin loses efficacy in this model of pain in CB1 knockout mice [50].”
Scott, D. A., Wright, C. E., & Angus, J. A. (2004) · Pain · doi:10.1016/j.pain.2004.01.020 · Cited by 128
Hohmann, A. G., Tsou, K., & Walker, J. M. (1999) · Journal of Neurophysiology · doi:10.1152/jn.1999.81.2.575 · Cited by 126 · cited 5×
“The cellular actions of cannabinoids on supraspinal and spinal descending antinociception pathways have also been studied [56, 162, 163].”
InfluentialSwift, W., Hall, W., & Teesson, M. (2001) · Addiction · doi:10.1046/j.1360-0443.2001.9657379.x · Cited by 126
Pugh, G., Smith, P. B., Dombrowski, D. S., & Welch, S. P. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)21168-5 · Cited by 123 · cited 1×
“This relation is confirmed by observations, as a reduced cannabinoid and opioid receptor agonist synergistic analgesia in prodynorphin knockout animals or after administering opioid receptor antagonists like, nor-binaltor-phimine (a kappa antagonist) or naltrindole (a delta antagonist), or antibodies against dynorphin…”
Berman, J., Lee, J., Cooper, M., Cannon, A., Sach, J., McKerral, S., Taggart, M., Symonds, C., Fishe, K., & Birch, R. (2003) · Anaesthesia · doi:10.1046/j.1365-2044.2003.03408_3.x · Cited by 122
mu-Opioid agonists inhibit spinal trigeminal substantia gelatinosa neurons in guinea pig and rat
Grudt, T., & Williams, J. (1994) · The Journal of Neuroscience · doi:10.1523/jneurosci.14-03-01646.1994 · Cited by 121 · cited 1×
“For instance, -opioid receptor agonists inhibit release of glutamate from primary afferent terminals at the level of the spinal and medullary dorsal horn, while CB1 receptors do not have any inhibitory effect on those excitatory neurons [49, 81].”
Cannabinoid Transmission and Pain Perception
Martin, B. R., & Lichtman, A. H. (1998) · Neurobiology of Disease · doi:10.1006/nbdi.1998.0218 · Cited by 117
Maurer, M., Henn, V., Dittrich, A., & Hofmann, A. (1990) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf02190083 · Cited by 117
Russo, E. (1998) · Pain · doi:10.1016/s0304-3959(98)00033-5 · Cited by 117
Hohmann, A. G., & Herkenham, M. A. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00534-5 · Cited by 115
Cannabinoid-induced antinociception is mediated by a spinalα2-noradrenergic mechanism
Lichtman, A. H., & Martin, B. R. (1991) · Brain Research · doi:10.1016/0006-8993(91)90017-p · Cited by 114 · cited 1×
“simple additivity in the tail-flick assay and synergism in the hot-plate assay [88].”
Gopez, J. J., Yue, H., Vasudevan, R., Malik, A. S., Fogelsanger, L. N., Lewis, S., Panikashvili, D., Shohami, E., Jansen, S. A., Narayan, R. K., et al. (2005) · Neurosurgery · doi:10.1227/01.neu.0000154060.14900.8f · Cited by 113
Hohmann, A. G., Tsou, K., & Walker, J. M. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00802-7 · Cited by 112 · cited 1×
“Following noxious heat stimulation, cannabinoid receptor agonists diminish stimulation in deep dorsal horn neurons, while the CB1-specific antagonist SR141716A facilitates nociceptive responses [18, 60].”
Cannabinoid CB1 receptor upregulation in a rat model of chronic neuropathic pain
Siegling, A., Hofmann, H. A., Denzer, D., Mauler, F., & De Vry, J. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)00798-1 · Cited by 108 · cited 1×
“For example, animal models of neuropathic pain stimulate upregulation of CB1 receptors expression in nervous structures involved in the processing of pain, like the ipsilateral superficial spinal cord dorsal horn [90] or contralateral thalamus [145], enhancing the analgesic effects of cannabinoid receptor agonists.”
Chieng, B., & Christie, M. J. (1994) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1994.tb16209.x · Cited by 107 · cited 6×
“Electrophysiologic analysis of the effects of cannabinoids on RVM has revealed that cannabinoids have effects similar to those elicited by morphine [104].”
InfluentialThe rodent amygdala contributes to the production of cannabinoid-induced antinociception
Manning, B. H., Martin, W. J., & Meng, I. D. (2003) · Neuroscience · doi:10.1016/s0306-4522(03)00356-7 · Cited by 105 · cited 1×
“Activation of cannabinoid receptors inhibits GABAergic synaptic transmission in a number of central nervous system regions, including areas participating in nociceptive signalling like the amygdala [93], periaqueductal grey matter [162], rostral ventromedial medulla (RVM) [163], and superficial dorsal horn [72].”
Two distinctive antinociceptive systems in rats with pathological pain
Mao, J., Price, D. D., Lü, J., Keniston, L., & Mayer, D. J. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00998-2 · Cited by 104 · cited 2×
“Therefore, since the pathways used for cannabinoid receptors-mediated analgesia at the level of the superficial dorsal horn are different from those characterised for -opioid receptormediated analgesia, it may explain why cannabinoid receptor agonists retain their efficacy, in contrast with morphine, in animal models…”
Raft, D., Gregg, J., Ghia, J., & Harris, L. (1977) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt197721126 · Cited by 103 · cited 2×
“Raft et al., 1977 [129] Healthy volunteers -THC 0.022 mg/kg i.v. -THC 0.044 mg/kg i.v.”
InfluentialMukhopadhyay, S., Chapnick, B. M., & Howlett, A. C. (2002) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00497.2001 · Cited by 100
Possible involvement of the endocannabinoid system in the actions of three clinically used drugs
Fowler, C. J. (2003) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2003.12.001 · Cited by 96 · cited 1×
“The enhancement of CB1 receptors activity by some NSAIDs (indomethacin, fluribuprofen) has been confirmed [37].”
Spinal mechanisms ofΔ9-tetrahydrocannabinol-induced analgesia
Smith, P. B., & Martin, B. R. (1992) · Brain Research · doi:10.1016/0006-8993(92)90222-u · Cited by 91
Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain
Staquet, M., Gantt, C., & Machin, D. (1978) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1978234397 · Cited by 90
Corchero, J., Avila, M. A., Fuentes, J. A., & Manzanares, J. (1997) · Life Sciences · doi:10.1016/s0024-3205(97)00405-0 · Cited by 86 · cited 2×
“On the other hand, cannabinoid receptor agonists induce the synthesis and/or release of endogenous opioid peptides [25, 94].”
Self-citationAjulemic acid: A novel cannabinoid produces analgesia without a “high”
BURSTEIN, S. H., Karst, M., Schneider, U., & Zurier, R. B. (2004) · Life Sciences · doi:10.1016/j.lfs.2004.04.010 · Cited by 85 · cited 2×
“The THC analogues most often used for preclinical or therapeutic purposes in humans are dronabinol, nabilone, levonantradol , CT-3 (or ajulemic acid), and HU211 [15, 117].”
Cannabinoid/Opioid Crosstalk in the Central Nervous System
Corchero, J., Manzanares, J., & Fuentes, J. A. (2004) · Critical Reviews™ in Neurobiology · doi:10.1615/critrevneurobiol.v16.i12.170 · Cited by 83
Self-citationStrangman, N. M., & Walker, J. M. (1999) · Journal of Neurophysiology · doi:10.1152/jn.1999.82.1.472 · Cited by 81 · cited 1×
“Interestingly, CB1 receptor agonists administered systemically exert analgesic effects on wind-up (elicited by transcutaneous stimulation) in the dorsal horn [56, 152].”
Welch, S. P., Dunlow, L. D., Patrick, G. S., & Razdan, R. K. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)09617-x · Cited by 79
Efficacy in CB1 receptor‐mediated signal transduction
Howlett, A. C. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705881 · Cited by 79
Ates, M., Hamza, M., Seidel, K., Kotalla, C. E., Ledent, C., & Gühring, H. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02470.x · Cited by 78 · cited 2×
“However, this may not be the only mechanism because intraperitoneal administration of a nonselective FAAH inhibitor (phenylmethylsulfonyl fluoride) does not affect the response to the formalin test, while AM251 still antagonises its analgesic effect [3].”
Grudt, T. J., & Henderson, G. (1998) · The Journal of Physiology · doi:10.1111/j.1469-7793.1998.473bt.x · Cited by 77 · cited 1×
“Moreover, -opioid receptors presynaptically inhibit both glycinergic and GABAergic synaptic transmission in the medullary dorsal horn [48], but not in the spinal cord [81], as occurs with CB1 receptors.”
Anti-inflammatory potential of CB1-mediated cAMP elevation in mast cells
SMALL-HOWARD, A. L., SHIMODA, L. M. N., ADRA, C. N., & TURNER, H. (2005) · Biochemical Journal · doi:10.1042/bj20041682 · Cited by 77 · cited 2×
“Peripheral cannabinoid receptors are less abundant than in central nervous system areas and non-neuronal cells located near nociceptive neuronal nerve endings are involved in the modulation of pro-inflammatory factors released [66, 146, 160].”
CB1 receptor localization in rat spinal cord and roots, dorsal root ganglion, and peripheral nerve.
Sañudo-Peña, M. C., Strangman, N. M., Mackie, K., Walker, J. M., & Tsou, K. (1999) · PubMed · Cited by 74
Chapman, V. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702758 · Cited by 72 · cited 1×
“Following noxious heat stimulation, cannabinoid receptor agonists diminish stimulation in deep dorsal horn neurons, while the CB1-specific antagonist SR141716A facilitates nociceptive responses [18, 60].”
Cannabinoids as potential new analgesics
Fuentes, J., Ruiz‐Gayo, M., Manzanares, J., Vela, G., Reche, I., & Corchero, J. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00290-8 · Cited by 72 · cited 1×
“Interestingly, this action is inhibited by either cannabinoid or opioid receptors antagonists separately, as demonstrated in acute [41] and chronic pain models [147, 174].”
Self-citationLópez-Rodríguez, M. L., Viso, A., Ortega-Gutiérrez, S., Lastres-Becker, I., González, S., Fernández-Ruiz, J., & Ramos, J. A. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm015545y · Cited by 70 · cited 1×
“2) [91].”
Ashton, C. H., Holdcroft, A., de Mars, S., Moffat, A. C., Pertwee, R. G., & Wall, P. D. (1997) · Cited by 69
Amino Acid Determinants in Cyclooxygenase-2 Oxygenation of the Endocannabinoid Anandamide
Kozak, K. R., Prusakiewicz, J. J., Rowlinson, S. W., Prudhomme, D. R., & Marnett, L. J. (2003) · Biochemistry · doi:10.1021/bi034471k · Cited by 68
(+)-Cannabidiol analogues which bind cannabinoid receptors but exert peripheral activity only
Fride, E., Feigin, C., Ponde, D. E., Breuer, A., Hanuš, L., Arshavsky, N., & Mechoulam, R. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.10.049 · Cited by 67
Cannabinoid actions on rat superficial medullary dorsal horn neurons in vitro
Jennings, E. A., Vaughan, C. W., & Christie, M. J. (2001) · The Journal of Physiology · doi:10.1111/j.1469-7793.2001.00805.x · Cited by 65 · cited 3×
“conductance from primary afferents in lamina II neurons in the medullary dorsal horn, further supporting a lack of cannabinoid influence on excitatory synapses at this spinal level [72].”
Early clinical manifestations of cannabis dependence in a community sample
Rosenberg, M. F., & Anthony, J. C. (2001) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(00)00229-5 · Cited by 59 · cited 1×
“It has been claimed that tolerance develops after repeated administration of THC in humans, that 9-20% of regular cannabis users become dependent, and that a significant withdrawal syndrome occurs in human cannabis users [2, 136, 153].”
Hill, S. Y., Schwin, R., Goodwin, D. W., & Powell, B. J. (1974) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)29765-8 · Cited by 53 · cited 2×
“, 1974 [55] Healthy volunteers”
Fimiani, C., Liberty, T., Aquirre, A. J., Amin, I., Ali, N., & Stefano, G. B. (1999) · Prostaglandins & Other Lipid Mediators · doi:10.1016/s0090-6980(98)00068-9 · Cited by 52 · cited 1×
“An interaction between cannabinoids and inhibitors of prostaglandin biosynthesis (like NSAIDs) has been reported, and it appears to be due to the similarity in chemical structure of endogenous cannabinoid ligands and prostaglandins (arachidonic acid derivatives), and to the convergence of prostaglandin and endocannabi…”
Effect of benzopyranoperidine, a Δ‐9‐THC congener, on pain
Jochimsen, P. R., Lawton, R. L., VerSteeg, K., & Noyes, R. (1978) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1978242223 · Cited by 51 · cited 1×
“Another derivative, benzopyranoperidine, produces a degree of sedation similar to codeine but is ineffective as an analgesic [73].”
Antisense oligodeoxynucleotide treatment to the brain cannabinoid receptor inhibits antinociception
Edsall, S. A., Knapp, R. J., Vanderah, T. W., Roeske, W. R., Consroe, P., & Yamamura, H. I. (1996) · NeuroReport · doi:10.1097/00001756-199601310-00052 · Cited by 43 · cited 1×
“Further confirmation of the role of the endocannabinoid system in the control of pain is that the blockade of cannabinoid receptors, whether by antagonists, antibodies, or genetic deletion, inhibits or attenuates pain perception [22] [33] [86].”
Effects of Moderate and High Doses of Marihuana on Thermal Pain: A Sensory Decision Theory Analysis
CLARK, W. C., JANAL, M. N., ZEIDENBERG, P., & NAHAS, G. G. (1981) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1981.tb02608.x · Cited by 43 · cited 2×
“, 1981 [20] Healthy volunteers being regular”
Clinical Experience with Nabilone for Chronic Pain
Notcutt, W. G., Price, M., & Chapman, G. (1997) · Pharmacy and Pharmacology Communications · doi:10.1111/j.2042-7158.1997.tb00493.x · Cited by 40
Structural requirements for cannabinoid-induced antinociceptive activity in mice
Martin, B. R. (1985) · Life Sciences · doi:10.1016/0024-3205(85)90376-5 · Cited by 40 · cited 1×
“THC is the substance with the greatest psychoactive potency of the natural cannabinoids, and exhibits the greatest analgesic activity [96].”
Marijuana-Produced Changes in Pain Tolerance. Experienced and Non-Experienced Subjects
Milstein, S. L., MacCannell, K., Karr, G., & Clark, S. (1975) · International Pharmacopsychiatry · doi:10.1159/000468188 · Cited by 40 · cited 1×
“Milstein et al., 1975 [105] Healthy volunteers -cannabis-experienced -naive subjects • cannabis smoked • placebo Pressure stimuli Smoked cannabis increased antinociceptive effects.”
Cannabis for Chronic Pain: Case Series and Implications for Clinicians
Ware, M. A., Gamsa, A., Persson, J., & Fitzcharles, M.-A. (2002) · Pain Research and Management · doi:10.1155/2002/380509 · Cited by 38
Pugh, G., Abood, M. E., & Welch, S. P. (1995) · Brain Research · doi:10.1016/0006-8993(95)00560-d · Cited by 37 · cited 1×
“This relation is confirmed by observations, as a reduced cannabinoid and opioid receptor agonist synergistic analgesia in prodynorphin knockout animals or after administering opioid receptor antagonists like, nor-binaltor-phimine (a kappa antagonist) or naltrindole (a delta antagonist), or antibodies against dynorphin…”
Delta 9-tetrahydrocannabinol increases arachidonic acid levels in guinea pig cerebral cortex slices.
Reichman, M., Nen, W., & Hokin, L. E. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10127-2 · Cited by 35 · cited 1×
“In addition, there is evidence that the addition of cannabinoid compounds to brain tissue sections originates an accumulation of arachidonic acid [130].”
Zeidenberg, P., Clark, W. C., Jaffe, J., Anderson, S. W., Chin, S., & Malitz, S. (1973) · Comprehensive Psychiatry · doi:10.1016/0010-440x(73)90040-0 · Cited by 34 · cited 1×
“Zeidenberg et al., 1973 [177] Healthy volunteers n=4 THC 5 mg p.o.”
Looking Back at Cannabis Research
Mechoulam, R. (2000) · Current Pharmaceutical Design · doi:10.2174/1381612003399509 · Cited by 33 · cited 2×
“Therefore one of them, HU-308 [102], does not produce hypothermia, catalepsy, or behavioural changes, while the role of CB2 receptors is fundamental in other cannabimimetic actions, such as immunomodulatory and antiproliferative effects.”
Luo, C., Kumamoto, E., Furue, H., Chen, J., & Yoshimura, M. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02471-5 · Cited by 32 · cited 1×
“CB1 receptors are also expressed in cells of the midbrain periaqueductal grey matter (PAG), and in the substantia gelatinosa of the spinal cord (receiving nociceptive input from primary afferent neurons), which are key sites for modulating nociceptive information [87, 92, 106].”
Drug of abuse profile: cannabis.
Rt, J. (1987) · PubMed · Cited by 30
Noyes, R., & BARAM, D. A. (1974) · Comprehensive Psychiatry · doi:10.1016/0010-440x(74)90008-x · Cited by 30
How Cannabinoids Work in the Brain
Barinaga, M. (2001) · Science · doi:10.1126/science.291.5513.2530 · Cited by 28 · cited 1×
“Cannabinoid receptor agonists modulate nociceptive thresholds by regulating neuronal activity [4], but they also relieve pain by acting on non-nervous tissues.”
Holt, S., & Fowler, C. J. (2003) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-002-0686-z · Cited by 27 · cited 11×
“It interacts with FAAH and the anandamide transporter.”
InfluentialMedicinal cannabis extracts for the treatment of multiple sclerosis.
Smith, P. F. (2004) · PubMed · Cited by 26
Raffa, R. B., Stone, D. J., & Hipp, S. J. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00096-8 · Cited by 20 · cited 1×
“Also, cannabinoid-induced antinociception can be attenuated by pertussis toxin and other substances that interfere with the signal transduction of CB1 receptors connected to protein G [128].”
Evaluation of cAMP involvement in cannabinoid-induced antinociception
Cook, S. A., Welch, S. P., Lichtman, A. H., & Martin, B. R. (1995) · Life Sciences · doi:10.1016/0024-3205(95)00188-c · Cited by 16 · cited 1×
“CB1, 2-adrenergic, and -opioid receptors are all Gprotein coupled receptors sharing signal transduction pathways, such as those inhibiting adenylate cyclase and modulating K + and Ca 2+ channels activity [24, 62, 80, 94, 124].”
Emerging analgesics in cancer pain management
Radbruch, L., & Elsner, F. (2005) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.10.1.151 · Cited by 11
Behavioral Tolerance: Lessons Learned from Cannabis Research
Jones, R. T. (1978) · PsycEXTRA Dataset · doi:10.1037/e497412006-013 · Cited by 10
Research works printed but not linked: 1
- [47]Grinspoon L, Bakalar JB. Marihuana the forbidden medicine. New Haven: Yale University Press; 1997. [Google Scholar]
Cited by
EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision
Attal, N., Cruccu, G., Baron, R., Haanpää, M., Hansson, P., Jensen, T. S., & Nurmikko, T. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.02999.x · Cited by 1,873
Pathological and protective roles of glia in chronic pain
Milligan, E. D., & Watkins, L. R. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2533 · Cited by 1,399
“For example, cannabinoid receptors, both type 1 (CB1) and type 2 (CB2), are being explored as therapeutic targets for inflammatory neurodegenerative diseases and neuropathic pai”
BackgroundThe effect of pain on cognitive function: A review of clinical and preclinical research
Moriarty, O., McGuire, B. E., & Finn, D. P. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.01.002 · Cited by 1,122
“Cannabinoid ligands have also demonstrated antinociceptive effects in acute, inflammatory and neuropathic pain models (Finn and Chapman, 2004; Manzanares et al., 2006), and have a synergistic analgesic effect when coadministered with opioids (Welch and Eads, 1999).”
Backgroundβ‐caryophyllene and β‐caryophyllene oxide—natural compounds of anticancer and analgesic properties
Fidyt, K., Fiedorowicz, A., Strządała, L., & Szumny, A. (2016) · Cancer Medicine · doi:10.1002/cam4.816 · Cited by 674
“In contrast, indirect analgesic responses are related to inhibition of the release of proinflammatory factors or/and may engage other systems involved in analgesia, such as endogenous opioid system [64].”
BackgroundCannabinoids and Cytochrome P450 Interactions
Zendulka, O., Dovrtělová, G., Nosková, K., Turjap, M., Šulcová, A., Hanuš, L., & Juřica, J. (2016) · Current Drug Metabolism · doi:10.2174/1389200217666151210142051 · Cited by 291
“N-arachidonoyldopamine (NADA) is another endocannabinoid known to exert significant biological activity, e.g. in the immune system and pain perception [59, 60].”
BackgroundMethodInfluential
Metadata
- Authors
- Manzanares, J., Julian, M., & Carrascosa, A.
- Affiliations
- Consejo Superior de Investigaciones Científicas (ES)
- Corresponding author
- Carrascosa, A.
- Venue
- Current Neuropharmacology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2006-07-01
- Volume
- 4
- Issue
- 3
- Pages
- 239-257
- ISSN
- 1570-159X (ISSN-L)
- PMC
- PMC2430692
- OpenAlex
- W2166781208
- Cited by
- 287
- References
- 179
- Citations by year
- 2026: 13 · 2025: 21 · 2024: 19 · 2023: 27 · 2022: 23 · 2021: 30 · 2020: 28 · 2019: 16 · 2018: 16 · 2017: 24 · 2016: 13 · 2015: 13 · 2014: 11 · 2013: 6 · 2012: 9
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Current Neuropharmacology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- endocannabinoid system, pain management, cannabinoid receptor agonists, acute pain, chronic pain, neuropathic pain, inflammatory pain, CB1 receptor, CB2 receptor, endocannabinoids, opioid system, mast cell activation, multiple sclerosis, tetrahydrocannabinol, cannabidiol, Cannabis sativa, analgesia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.